drugset / Trial / NCT00896454

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

NCT00896454

Phase 2 Completed 33 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dL (2.9 millimoles /L) by day 10.

Timeline

Start
2009-11-16
Primary completion
2012-09-13
Completion
2013-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous